Filing Details
- Accession Number:
- 0001250853-18-000041
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-03-14 20:32:30
- Reporting Period:
- 2018-03-12
- Accepted Time:
- 2018-03-14 20:32:30
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1561743 | Kindred Biosciences Inc. | KIN | Pharmaceutical Preparations (2834) | 461160142 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1593867 | Raymond Townsend | C/O Kindred Biosciences, Inc. 1555 Bayshore Highway, Suite 200 Burlingame CA 94010 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-03-12 | 91 | $3.45 | 23,233 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-03-12 | 91 | $9.45 | 23,142 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2018-03-12 | 155 | $3.45 | 23,297 | No | 4 | M | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2018-03-12 | 91 | $0.00 | 91 | $3.45 |
| Common Stock | Stock Option (right to buy) | Disposition | 2018-03-12 | 155 | $0.00 | 155 | $3.45 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 26,348 | 2026-01-08 | No | 4 | M | Direct | |
| 26,193 | 2026-01-08 | No | 4 | M | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2017.
- The option vested 25% quarterly following January 8, 2016, the date of grant.
Billionaire Hedge Funds
